The global pharmaceutical industry experienced a 15% rise in company filings mentions of orphan designated drugs in Q2 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics, according to GlobalData’s analysis of over 62 pharmaceutical company filings. GlobalData’s New Drug Approvals and Their Contract Manufacture report provides critical insight into the contract manufacturing organization (CMO) industry by analysing relative performance of major CMOs by number of drug and vaccine approvals, and the outsourcing propensity for New Molecular Entities (NMEs) includin Buy the report here.
Notably, orphan designated drugs was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of big data and precision and personalized medicine, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Sarepta Therapeutics had the greatest increase in references for orphan designated drugs in Q2 2023, compared with the previous quarter. GlobalData identified two orphan designated drugs-related sentences in the company's filings - 0.1% of all sentences - and an increase of 100% in Q2 2023 compared with Q2 2022.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for orphan designated drugs in Q2 2023 was 121.
For further understanding of GlobalData's New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.